Stage-Related Effect of Statin Treatment on the Progression of Aortic Valve Sclerosis and Stenosis

American Journal of Cardiology

Volumn 102, Issue 6, 2008, Pages 738-742

  Antonini Canterin, Francesco ^a   Hîrşu, Monica ^b   Popescu, Bogdan Alexandru ^b   Leiballi, Elisa ^a   Piazza, Rita ^a   Pavan, Daniela ^a   Ginghinǎ, Carmen ^b   Nicolosi, Gian Luigi ^a  

^a S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^b Prof Dr C C Iliescu Institute of Cardiovascular Diseases   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; AORTA VALVE STENOSIS; ARTICLE; BLOOD FLOW VELOCITY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 50949107980     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.04.056     Document Type: Article

References (21)

1. Stewart B.F., Siscovick D., Lind B.K., Gardin J.M., Gottdiener J.S., Smith V.E., Kitzman D.W., and Otto C.M. Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol 29 (1997) 630-634
2. Bonow R.O., Carabello B.A., Chatterjee K., de Leon Jr. A.C., Faxon D.P., Freed M.D., Gaasch W.H., Lytle B.W., Nishimura R.A., O'Gara P.T., et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 48 (2006) e1-e148
3. Aronow W.S., Ahn C., Kronzon I., and Goldman M.E. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 88 (2001) 693-695
4. Bellamy M.F., Pellikka P.A., Klarich K.W., Tajik A.J., and Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 40 (2002) 1723-1730
5. Novaro G.M., Tiong I.Y., Pearce G.L., Lauer M.S., Sprecher D.L., and Griffin B.P. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104 (2001) 2205-2209
6. Rosenhek R., Rader F., Loho N., Gabriel H., Heger M., Klaar U., Schemper M., Binder T., Maurer G., and Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110 (2004) 1291-1295
7. Moura L.M., Ramos S.F., Zamorano J.L., Barros I.M., Azevedo L.F., Rocha-Goncalves F., and Rajamannan N.M. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 49 (2007) 554-561
8. Cowell S.J., Newby D.E., Prescott R.J., Bloomfield P., Reid J., Northridge D.B., and Boon N.A. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352 (2005) 2389-2397
9. Otto C.M. Why is aortic sclerosis associated with adverse clinical outcomes?. J Am Coll Cardiol 43 (2004) 176-178
10. Cosmi J.E., Kort S., Tunick P.A., Rosenzweig B.P., Freedberg R.S., Katz E.S., Applebaum R.M., and Kronzon I. The risk of development of aortic stenosis in patients with "benign" aortic valve thickening. Arch Intern Med 162 (2002) 2345-2347
11. Douglas P.S., Khandheria B., Stainback R.F., and Weissman N.J. Appropriateness criteria for transthoracic and transesophageal echocardiography. J Am Coll Cardiol 50 (2007) 187-204
12. Antonini-Canterin F., Popescu B.A., Huang G., Korcova-Miertusova R., Rivaben D., Faggiano P., Pavan D., Piazza R., Bolis A., Ciavattone A., Ruggiero A., and Nicolosi G.L. Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment?. Ital Heart J 6 (2005) 119-124
13. Cheitlin M., Armstrong W.F., Aurigemma G.P., Beller G.A., Bierman F.Z., Davis J.L., Douglas P.S., Faxon D.P., Gillam L.D., Kimball T.R., et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am SocEchocardiogr 16 (2003) 1091-1110
14. Bland J.M., and Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1 (1986) 307-310
15. Rossebø A.B., Pedersen T.R., Allen C., Boman K., Chambers J., Egstrup K., Gerdts E., Gohlke-Barwolf C., Holme I., Kesaniemi V.A., et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol 99 (2007) 970-973
16. Chan K.L., Teo K., Tam J., and Dumesnil J.G. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: The Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Am Heart J 153 (2007) 925-931
17. Liebe V., Brueckmann M., Borggrefe M., and Kaden J.J. Statin therapy of calcific aortic stenosis: hype or hope?. Eur Heart J 27 (2006) 773-778
18. Griffin B.P. Statins in aortic stenosis. J Am Coll Cardiol 49 (2007) 562-564
19. Goldbarg S.H., Elmariah S., Miller M.A., and Fuster V. Insights into degenerative aortic valve disease. J Am Coll Cardiol 50 (2007) 1205-1213
20. Otto C.M., and O'Brien K.D. Why is there discordance between calcific aortic stenosis and coronary artery disease?. Heart 85 (2001) 601-602
21. Otto C.M., Lind B.K., Kitzman D.W., Gersh B.J., and Siscovick D.S. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 341 (1999) 142-147